ANI Pharmaceuticals (NASDAQ:ANIP) is the biotech of the week on the Fool's weekly show Biotech Banter. Watch the following video, where senior biotech specialist Brian Orelli and health-care bureau chief Max Macaluso discuss the generic-drug company that went public last year through a merger with BioSante.
Since then the company acquired some already-approved generic drugs from Teva Pharmaceuticals (NYSE:TEVA) and set up partnerships with Sofgen Pharmaceuticals and Sterling Pharmaceutical Services.
In addition to sales of its generic-drug products, ANI Pharmaceuticals has potential for milestones and royalties from BioSante's legacy programs: a testosterone gel licensed to Teva and a portfolio of cancer vaccines licensed to Aduro BioTech.
The small generic-drug maker might have trouble competing with Teva, Novartis (NYSE:NVS), and the rest of the big boys, but ANI Pharmaceuticals may be able to find a niche and potentially be a takeout target down the road.